Biohaven (BHVN) to Release Earnings on Thursday

Biohaven (NYSE:BHVN - Get Free Report) is expected to issue its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($1.56) per share for the quarter.

Biohaven Price Performance

Shares of BHVN traded up $0.55 during mid-day trading on Friday, reaching $37.09. The company's stock had a trading volume of 766,114 shares, compared to its average volume of 868,729. Biohaven has a 12-month low of $26.80 and a 12-month high of $62.21. The stock has a market cap of $3.75 billion, a PE ratio of -3.97 and a beta of 1.28. The company's 50 day moving average is $38.24 and its 200 day moving average is $42.73.

Insider Transactions at Biohaven

In other news, Director John W. Childs acquired 29,000 shares of the stock in a transaction that occurred on Monday, December 30th. The shares were purchased at an average cost of $35.94 per share, for a total transaction of $1,042,260.00. Following the transaction, the director now directly owns 2,368,741 shares in the company, valued at approximately $85,132,551.54. This represents a 1.24 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 16.00% of the company's stock.

Analyst Ratings Changes

BHVN has been the topic of a number of research analyst reports. TD Cowen raised their price objective on shares of Biohaven from $55.00 to $75.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Biohaven in a research note on Tuesday, February 11th. They set a "buy" rating and a $65.00 price target on the stock. Royal Bank of Canada reaffirmed an "outperform" rating and set a $61.00 price objective (up previously from $58.00) on shares of Biohaven in a report on Wednesday, December 4th. Cantor Fitzgerald reissued an "overweight" rating on shares of Biohaven in a report on Tuesday, December 17th. Finally, HC Wainwright restated a "buy" rating and set a $59.00 price target on shares of Biohaven in a research note on Tuesday, December 17th. Fourteen equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $63.15.

Remove Ads

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.